Atypical antipsychotic drugs upregulate synapsin II in the prefrontal cortex of post-mortem samples obtained from patients with schizophrenia

Schizophrenia Research

Volumn 120, Issue 1-3, 2010, Pages 229-231

  Guest, Kelly A ^a   Dyck, Bailee A ^a   Shethwala, Shazli ^a   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NEUROLEPTIC AGENT; SYNAPSIN II; SYNAPSIN IIA; SYNAPSIN IIB; UNCLASSIFIED DRUG; MESSENGER RNA; SYNAPSIN;

ADULT; AGED; AUTOPSY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCHIZOPHRENIA; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POSTMORTEM CHANGE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; PREFRONTAL CORTEX; RNA, MESSENGER; SCHIZOPHRENIA; SYNAPSINS; UP-REGULATION;

EID: 77954143022     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.029     Document Type: Letter

References (10)

1. Chen Q., Guang H., Xiao Y.W., Qing C., Xin L.M., Zhong G.Z., Jie L., Ke Qing L., Wang S.J., Zhu S.M., Feng G., He L. Positive association between synapsin II and schizophrenia. Biol. Psychiatry 2004, 56(3):177-181.
2. Chong V.Z., Young T., Mishra R.K. cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J. Neurochem. 2002, 82(6):1533-1539.
3. Chong V.Z., Skoblenick K., Morin F., Xu Y., Mishra R.K. Dopamine-D1 and -D2 receptors differentially regulate synapsin II expression in the rat brain. Neurosci. 2006, 138(2). 587-99.
4. Dyck B.A., Skoblenick K.J., Castellano J.M., Ki K., Thomas N., Mishra R.K. Synapsin II knockout mice show sensorimotor gating and behavioural abnormalities similar to those in the phencyclidine-induced preclinical animal model of schizophrenia. Schizophr. Res. 2007, 97(1-3). 292-93.
5. Farde L., Nordstrom A.L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatry 1992, 160(17):30-33.
6. Ferreira A., Rapoport M. The synapsins: beyond the regulation of neurotransmitter release. Cell Mol. Life Sci. 2002, 59(4):589-595.
7. Frankle W.G., Lerma J., Laruelle M. The synaptic hypothesis of schizophrenia. Neuron 2003, 39(2):205-216.
8. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28(1):53-67.
9. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 2008, 13(1):27-35.
10. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 2002, 47(1):27-38.